As been shown for prostate-specific antigen (PSA/ KLK3) in prostate cancer, these may represent potential novel biomarkers for ovarian carcinoma (Borgono and Diamandis, 2004).
This was shown for prostate, bladder, breast and thyroid cancer by Villanueva et al [10], [11].
Similar figures were shown for prostate cancer.
The importance of FABPs for the progression of carcinomas was shown for prostate cancer [ 8], breast cancer [ 9], bladder cancer [ 10] and astrocytomas [ 11].
There are several reports documenting that the VE analogue potentiates cancer cells killing by the immunological apoptogen Fas, viz by mobilising the Fas receptor from the cytosol to the plasma membrane; this has been shown for both prostate and breast cancer cells (Turley et al, 1997; Yu et al, 1999).
The production of 500-600 μm large spheroids from various epithelial cancer cell lines has already been shown for colon, breast, prostate and kidney but not pancreas with the liquid overlay technology [ 18].
The hematopoietic stem cell niche in the bone has been shown, for example, to provide prostate cancer cells with the microenvironment they require for metastasis formation [ 41, 42].
These allele-disease associations have already been shown for CYP3A gene polymorphisms and prostate, breast and lung cancer [ 37- 43], albeit with controversial results.
Good clinical value has been shown for restaging of biologically relapsed prostate cancer, including detection of local recurrence, regional lymph node metastases and distant metastases [ 7].
Down-regulation of prostasin protein expression has been shown for high-grade and hormone-refractory prostate cancers [ 11, 12], breast cancers [ 13], and gastric cancers [ 14].
